Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Outset Medical, Inc. filings on SEC EDGAR ↗
Outset Medical reported total revenue of $33.6 million for the third quarter of 2026, an increase from $29.4 million in the prior year period. The company reduced its quarterly net loss to $14.7 million compared to $17.8 million in Q3 2025, driven by improved gross margins and lower operating expenses.
Outset Medical reported third quarter 2026 revenue of $33.6 million, a 14% increase year-over-year, driven by strong growth in console and recurring revenue. The company reduced its net loss to $14.7 million from $17.8 million in the prior-year period while expanding gross margins to 40.7%. Management reiterated its full-year 2026 revenue guidance of $125 million to $130 million.
Term
Q3 2026
“Third-quarter results demonstrated continued progress against our strategic priorities and solid sales execution across both capital and recurring revenue. Consistently strong customer satisfaction and retention are expanding adoption of Tablo across our existing customer base and fueling new insourced dialysis partnerships with leading health systems. Advancing our mission to help providers nationwide improve the cost, complexity and clinical outcomes of dialysis continues to position Outset well for sustained long-term growth and value creation.”
Outset Medical 10% Owner Braden Michael Leonard Buys $870K of Stock
Braden Michael Leonard, 10% Owner, bought 244,909 shares of Outset Medical, Inc. at $3.53 to $3.88 a share (average $3.55) in 2 transactions, worth $870K in total between Oct 1, 2026 and Oct 2, 2026. Shares held after the trade: 2,764,610 (+0.6%).